Prospects of imaging retinal amyloid beta using fluorescent probes for early diagnosis of Alzheimer’s disease

Xinyuan Hu

doi:10.54254/2753-8818/24/20231155

Research Article

Open access

Published on 20 December 2023

Download pdf

Hu,X. (2023). Prospects of imaging retinal amyloid beta using fluorescent probes for early diagnosis of Alzheimer’s disease. Theoretical and Natural Science,24,204-211.

Export citation

Prospects of imaging retinal amyloid beta using fluorescent probes for early diagnosis of Alzheimer’s disease

Xinyuan Hu *^,1,

¹ Westminster School

* Author to whom correspondence should be addressed.

https://doi.org/10.54254/2753-8818/24/20231155

Abstract

Alzheimer’s Disease is the most common cause of dementia amongst older adults, affecting more than 55 million people globally. Identifying accessibility concerns for conventional methods used for diagnostics, this review focuses on an alternative approach detecting amyloid beta in the retina. The utility of this biomarker is yet to be verified due to the low number of in vivo studies in AD patients, as well as the need for further investigation on the subtle differences between cerebral and retinal patterns of amyloid deposition. However, this approach has shown great promise as recent in vivo studies of larger sample sizes are conducted. Exemplifying the applications of curcumin, this paper also examines current methodologies in rAβ research and evaluates the outlook of chemically modifying fluorescent probes for oligomeric selectivity.

Keywords

Alzheimer’s Disease, Retinal Amyloid Beta, Curcumin, Amyloid Beta Oligomers

View pdf

References

[1]. Crous-Bou M, Minguillón C, Gramunt N, Molinuevo JL. Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimer’s Research & Therapy. 2017 Sep 12;9(1):71.

[2]. Retinal imaging in Alzheimer’s disease | Journal of Neurology, Neurosurgery & Psychiatry [Internet]. [cited 2023 Jul 25]. Available from: https://jnnp.bmj.com/content/92/9/983

[3]. Golzan SM, Goozee K, Georgevsky D, Avolio A, Chatterjee P, Shen K, et al. Retinal vascular and structural changes are associated with amyloid burden in the elderly: ophthalmic biomarkers of preclinical Alzheimer’s disease. Alzheimer’s Research & Therapy. 2017 Mar 1;9(1):13.

[4]. Gupta VB, Chitranshi N, Den Haan J, Mirzaei M, You Y, Lim JKh, et al. Retinal changes in Alzheimer’s disease— integrated prospects of imaging, functional and molecular advances. Progress in Retinal and Eye Research. 2021 May;82:100899.

[5]. Zhang J, Shi L, Shen Y. The retina: A window in which to view the pathogenesis of Alzheimer’s disease. Ageing Research Reviews. 2022 May 1;77:101590.

[6]. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018 Apr;14(4):535–62.

[7]. Amyloid beta: structure, biology and structure-based therapeutic development | Acta Pharmacologica Sinica [Internet]. [cited 2023 Aug 2]. Available from: https://www.nature.com/articles/aps201728

[8]. Sgourakis NG, Yan Y, McCallum S, Wang C, Garcia AE. The Alzheimer’s peptides Aβ40 and 42 adopt distinct conformations in water: A combined MD / NMR study. J Mol Biol. 2007 May 18;368(5):1448–57.

[9]. Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, et al. Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer’s disease. Lancet. 2003 Apr 12;361(9365):1258–65.

[10]. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010 Jan;9(1):119–28.

[11]. Detection of retinal and blood Aβ oligomers with nanobodies - Habiba - 2021 - Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring - Wiley Online Library [Internet]. [cited 2023 Aug 6]. Available from: https://alz-journals. onlinelibrary.wiley.com/doi/full/10.1002/dad2.12193

[12]. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, et al. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage. 2011 Jan 1;54:S204–17.

[13]. The AppNL-G-F mouse retina is a site for preclinical Alzheimer’s disease diagnosis and research - PMC [Internet]. [cited 2023 Aug 6]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788955/

[14]. Jiang J, Wang H, Li W, Cao X, Li C. Amyloid Plaques in Retina for Diagnosis in Alzheimer’s Patients: a Meta-Analysis. Front Aging Neurosci. 2016 Nov 10;8:267.

[15]. Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight [Internet]. 2017 Aug 17 [cited 2023 Aug 3];2(16). Available from: https://insight.jci.org/articles/view/93621

[16]. Dumitrascu OM, Lyden PD, Torbati T, Sheyn J, Sherzai A, Sherzai D, et al. Sectoral segmentation of retinal amyloid imaging in subjects with cognitive decline. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2020;12(1):e12109.

[17]. Penke B, Bogár F, Paragi G, Gera J, Fülöp L. Key Peptides and Proteins in Alzheimer’s Disease. CPPS. 2019 May 20;20(6):577–99.

[18]. Penke B, Szűcs M, Bogár F. Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer’s Pathogenesis. Molecules. 2020 Jan;25(7):1659.

[19]. Cline EN, Bicca MA, Viola KL, Klein WL. The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer’s Disease. 2018 Jan 1;64(s1):S567–610.

[20]. Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer’s Disease | Acta Neuropathologica Communications | Full Text [Internet]. [cited 2023 Aug 3]. Available from: https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-014-0135-5

[21]. Shin WS, Di J, Cao Q, Li B, Seidler PM, Murray KA, et al. Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation. Alzheimer’s Research & Therapy. 2019 Oct 18;11(1):86.

[22]. Sehar U, Rawat P, Reddy AP, Kopel J, Reddy PH. Amyloid Beta in Aging and Alzheimer’s Disease. International Journal of Molecular Sciences. 2022 Jan;23(21):12924.

[23]. Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics. Alz Res Therapy. 2014 Jul 9;6(4):42.

[24]. Koronyo Y, Rentsendorj A, Mirzaei N, Regis GC, Sheyn J, Shi H, et al. Retinal pathological features and proteome signatures of Alzheimer’s disease. Acta Neuropathol. 2023 Apr 1;145(4):409–38.

[25]. Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, et al. Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial. Alzheimers Dement (Amst). 2021 Aug 17;13(1):e12199.

[26]. Ratnayaka JA, Serpell LC, Lotery AJ. Dementia of the eye: the role of amyloid beta in retinal degeneration. Eye. 2015 Aug;29(8):1013–26.

[27]. More SS, Vince R. Hyperspectral Imaging Signatures Detect Amyloidopathy in Alzheimer’s Mouse Retina Well before Onset of Cognitive Decline. ACS Chem Neurosci. 2015 Feb 18;6(2):306–15.

[28]. Lee S, Jiang K, McIlmoyle B, To E, Xu Q (Alis), Hirsch-Reinshagen V, et al. Amyloid Beta Immunoreactivity in the Retinal Ganglion Cell Layer of the Alzheimer’s Eye. Frontiers in Neuroscience [Internet]. 2020 [cited 2023 Aug 5];14. Available from: https://www.frontiersin.org/articles/10.3389/fnins.2020.00758

[29]. Wang L, Mao X. Recent advancements toward non-invasive imaging of retinal amyloid-beta for early detection of Alzheimer’s disease. Neural Regeneration Research. 2022 Aug;17(8):1741.

[30]. McCormick JW, Ammerman L, Chen G, Vogel PD, Wise JG. Transport of Alzheimer’s associated amyloid-β catalyzed by P-glycoprotein. PLOS ONE. 2021 Apr 26;16(4):e0250371.

[31]. Kennedy BG, Mangini NJ. P-glycoprotein expression in human retinal pigment epithelium. Mol Vis. 2002 Nov 11;8:422–30.

[32]. Wang L, Mao X. Role of Retinal Amyloid-β in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications. International Journal of Molecular Sciences. 2021 Jan;22(5):2360.

[33]. Gupta V, Gupta VB, Chitranshi N, Gangoda S, Vander Wall R, Abbasi M, et al. One protein, multiple pathologies: multifaceted involvement of amyloid β in neurodegenerative disorders of the brain and retina. Cell Mol Life Sci. 2016 Nov 1;73(22):4279–97.

[34]. Dentchev T, Milam AH, Lee VMY, Trojanowski JQ, Dunaief JL. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis. 2003 May 14;9:184–90.

[35]. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer’s A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11830–5.

[36]. Masuzzo A, Dinet V, Cavanagh C, Mascarelli F, Krantic S. Amyloidosis in Retinal Neurodegenerative Diseases. Frontiers in Neurology [Internet]. 2016 [cited 2023 Aug 5];7. Available from: https://www.frontiersin.org/articles/10.3389/fneur.2016.00127

[37]. Schultz N, Byman E, Netherlands Brain Bank, Wennström M. Levels of Retinal Amyloid-β Correlate with Levels of Retinal IAPP and Hippocampal Amyloid-β in Neuropathologically Evaluated Individuals. J Alzheimers Dis. 2020;73(3):1201–9.

[38]. Yan Z, Liao H, Chen H, Deng S, Jia Y, Deng C, et al. Elevated Intraocular Pressure Induces Amyloid-β Deposition and Tauopathy in the Lateral Geniculate Nucleus in a Monkey Model of Glaucoma. Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5434–43.

[39]. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas | Acta Neuropathologica Communications | Full Text [Internet]. [cited 2023 Aug 5]. Available from: https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-018-0650-x

[40]. Gupta V, You Y, Li J, Gupta V, Golzan M, Klistorner A, et al. BDNF impairment is associated with age-related changes in the inner retina and exacerbates experimental glaucoma. Biochim Biophys Acta. 2014 Sep;1842(9):1567–78.

[41]. Ito Y, Shimazawa M, Tsuruma K, Mayama C, Ishii K, Onoe H, et al. Induction of amyloid-β1-42 in the retina and optic nerve head of chronic ocular hypertensive monkeys. Mol Vis. 2012 Oct 29;18:2647–xxx.

[42]. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of β amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Experimental Eye Research. 2004 Feb 1;78(2):243–56.

[43]. Jack CR, Garwood M, Wengenack TM, Borowski B, Curran GL, Lin J, et al. In Vivo Visualization of Alzheimer’s Amyloid Plaques by MRI in Transgenic Mice Without a Contrast Agent. Magn Reson Med. 2004 Dec;52(6):1263–71.

[44]. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008 Jul 15;14(14):4491–9.

[45]. Kayabasi UA, Cekmeceli SN. Retinal examination with curcumin in Alzheimer’s disease. BCHD. 2022 May 28;5(5):117.

[46]. Chin D, Huebbe P, Pallauf K, Rimbach G. Neuroprotective properties of curcumin in Alzheimer’s disease--merits and limitations. Curr Med Chem. 2013;20(32):3955–85.

[47]. Askarizadeh A, Barreto GE, Henney NC, Majeed M, Sahebkar A. Neuroprotection by curcumin: A review on brain delivery strategies. International Journal of Pharmaceutics. 2020 Jul 30;585:119476.

[48]. Cole GM, Teter B, Frautschy SA. NEUROPROTECTIVE EFFECTS OF CURCUMIN. Adv Exp Med Biol. 2007;595:197–212.

[49]. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, et al. Amyloid β-Protein Fibrillogenesis: STRUCTURE AND BIOLOGICAL ACTIVITY OF PROTOFIBRILLAR INTERMEDIATES *. Journal of Biological Chemistry. 1999 Sep 3;274(36):25945–52.

[50]. Li Y, Yang J, Liu H, Yang J, Du L, Feng H, et al. Tuning the stereo-hindrance of a curcumin scaffold for the selective imaging of the soluble forms of amyloid beta species. Chem Sci. 2017 Nov 1;8(11):7710–7.

[51]. Zhang X, Tian Y, Zhang C, Tian X, Ross AW, Moir RD, et al. Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9734–9.

[52]. Yang J, Zeng F, Li X, Ran C, Xu Y, Li Y. Highly specific detection of Aβ oligomers in early Alzheimer’s disease by a near-infrared fluorescent probe with a “V-shaped” spatial conformation. Chem Commun. 2020 Jan 7;56(4):583–6.

[53]. Teoh CL, Su D, Sahu S, Yun SW, Drummond E, Prelli F, et al. Chemical Fluorescent Probe for Detection of Aβ Oligomers. J Am Chem Soc. 2015 Oct 28;137(42):13503–9.

[54]. Versatile near-infrared fluorescent probe for in vivo detection of Aβ oligomers - ScienceDirect [Internet]. [cited 2023 Aug 7]. Available from: https://www.sciencedirect. com/science/article/abs/pii/S0968089620303898

[55]. Zhang X, Tian Y, Yuan P, Li Y, Yaseen MA, Grutzendler J, et al. A bifunctional curcumin analogue for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer’s disease. Chem Commun. 2014 Sep 4;50(78):11550–3.

[56]. Ran K, Yang J, Nair AV, Zhu B, Ran C. CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques. Molecules. 2020 Jan;25(4):863.

[57]. Yang H, Zeng F, Luo Y, Zheng C, Ran C, Yang J. Curcumin Scaffold as a Multifunctional Tool for Alzheimer’s Disease Research. Molecules. 2022 Jan;27(12):3879.

Cite this article

Hu,X. (2023). Prospects of imaging retinal amyloid beta using fluorescent probes for early diagnosis of Alzheimer’s disease. Theoretical and Natural Science,24,204-211.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 3rd International Conference on Biological Engineering and Medical Science

Conference website: https://www.icbiomed.org/

ISBN：978-1-83558-221-3(Print) / 978-1-83558-222-0(Online)

Conference date: 2 September 2023

Editor：Alan Wang

Series: Theoretical and Natural Science

Volume number: Vol.24

ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).